| INTRODUC TI ON
Epstein-Barr virus associated smooth muscle tumors (EBV-SMT) represent a rare lesion with a clinical course varying from indolent to malignant.
It is observed in settings where patients have impaired T-cell mediated immunity, such as human immunodeficiency virus infection, SOT and
hematopoietic stem cell transplantation.
1-3 EBV-SMT can be differentiated from primary leiomyosarcoma by the occurrence at sites atypical for primary leiomyosarcoma and the presence of EBV in situ hybridization (EBV-ISH) positivity. 2 These lesions behave with variable aggressiveness, and unlike in primary leiomyosarcoma their histologic grade does not correlate with outcomes. 4 A literature review starting with 2012 identified 68 reported cases of post-transplant EBV-SMT in 26 pediatric patients and 42 adults, 10 of which were heart transplant recipients.
Epstein-Barr virus-in situ hybridization positivity is a defining feature of post-transplant EBV-SMT, and this complication disproportionately affects children and young adults. This has lead to the speculation that primary EBV infection post transplant is important in its pathogenesis.
5
Despite this, pre-transplant serology that would confirm primary infection is seldom available in case reports/series and detailed EBV viral load kinetics antedating the EBV-SMT diagnosis have not been documented in these patients. Although EBV DNA persists at a very low level (set point) in all EBV seropositive individuals (mean 110/10 7 memory B cells), these levels are not detected by routine molecular assays for EBV DNA measurement. After primary EBV infection in immunocompetent hosts, EBV DNA was non-detectable in whole blood in all subjects by 202 days after first detection. 6 In contrast, patients experiencing EBV infection after SOT and in HIV patients, altered set points and persistently elevated viral loads may occur. 7 The Unviersity of Pittsburgh group has suggested that patients with >16 000 copies/mL of whole blood (4.2 log 10 copies/ mL) be considered to have a chronic high viral load phenotype.
8
Because EBV-SMT is a rare transplant complication, much of our knowledge is derived from case reports and case series. With the exception of a study of EBV-SMT by investigators at the Singapore General Hospital in kidney transplant recipients, the incidence and risk factors for EBV-SMT have not previously been reported, particularly in the context of the proportion of EBV seronegative patients at risk of primary EBV infection. 9 In this study, we report the incidence of posttransplant EBV-SMT over a thirty-one year period among the pediatric and adult patients receiving solid organ transplants at our center and describe the identified cases. Our data includes pre-transplant serology and EBV viral load measurements in whole blood both antedating and following the post-transplant EBV-SMT diagnosis, providing insight into the virology of EBV during the development of post-transplant EBV-SMT. We also performed an updated literature review, focusing on virology parameters, which provides context for our observations. 
| ME THODS

| Case selection and local incidence
| Review of the literature
Articles were abstracted by a MedLine search on all articles published before January 2018, inclusive. The MESH terms "leiomyosarcoma" or "smooth muscle tumor", and the keywords "EBV smooth-muscle tumor" or "spindle cell tumor" were combined with the keyword "transplantation". Additional articles were abstracted by a PubMed search on all articles published before January 2018, inclusive, with the search term "EBV smooth muscle tumor". The identified articles were screened for relevance and non-duplication.
The references were reviewed to find cases not captured by the initial search strategy. These data were extracted from all reports, and all quantitative EBV viral loads were converted to copies/mL using known conversion factors.
This study was approved by the Research Ethics and Management
Office at the University of Alberta (Pro00039242) and the Conjoint Health Research Ethics Board at the University of Calgary.
| RE SULTS
| Clinical case reports
| Case #1
A 5-month old female received an orthotopic heart transplant with incidental thymectomy for heart failure secondary to hypertrophic cardiomyopathy (Table 1 F I G U R E 1 EBV viral load graphs for three cases of post-transplant EBV-SMT -EBV viral load data (Y-axis, units log(copies/mL)) for the three identified cases of EBV-SMT in pediatric heart transplant recipients. Clinical events are marked at years post transplant with arrows, further detailed in Table 1 . Each number label corresponds to the respective case number. All three patients had sustained, high viral loads
| Case #2
An 8-month old female received an orthotopic heart transplant after a failed Norwood procedure for a hypoplastic left heart syndrome (Table 1 
| Case #3
A 23 month old female received an orthotopic heart transplantation for pulmonary atresia with a hypoplastic right ventricle. Incidental thymectomy had been performed previously (Table 1 case Lymph node, GI and bone marrow biopsies revealed an EBV-ISH positive polymorphic PTLD. Her EBV viral load at this point was 2500 genome copies/100 000 lymphocytes (50 000 copies/mL).
Tacrolimus was discontinued and she was treated with four doses of rituximab. There was clinical improvement, and her EBV viral load decreased. Cyclosporine was re-introduced, and she was maintained on intravenous immunoglobulin and oral ganciclovir. showed no other involved sites, and her EBV viral load was 5000 genome copies/100 000 lymphocytes (100 000 copies/mL). She received systemic chemotherapy with vincristine, doxorubicin, 
| Local incidence of post-transplant EBV-SMT
Post-transplant EBV-SMT occurred exclusively in pediatric heart recipients at our center (Jan 1984-Dec 2015) as summarized in Table 2 .
The complication occurred in 1.9% (95% CI: 0.4%-5.3%) of this subpopulation, giving an incidence rate of 2.6 (95% CI: 0.6-6.7) per 1000
person-years of follow-up in the pediatric heart transplant population, and an incidence rate of 0.7 (95% CI: 0.2-1.7) per 1000 person-years of follow-up. All affected children were EBV seronegative pre-transplant, compared to 60.7% of the pediatric heart recipients, 55.1%
of the pediatric recipients, and 4.2% of adult recipients. Within the pediatric subgroup, lung and kidney recipients were significantly older than heart and liver recipients (lung vs heart: P = 0.004, lung vs liver: P = 0.0008, kidney vs heart: P < 0.0001, kidney vs liver: P < 0.0001), but there was no significant difference in age (P = 0.46) or EBV seronegativity rates (P = 1) between heart and liver transplant recipients.
| Review of the literature
The initial MedLine search strategy generated 238 references, of which 25 were included. 
| D ISCUSS I ON
We report three cases of post-transplant EBV-SMT at our center.
All cases occured in EBV seronegative pediatric heart transplant TA B L E 2 EBV-SMT incidence in solid organ transplants at our institution from Jan 1984 -Dec 2015 for pediatric cases and 55% for adults. This is particularly disproportionate for adult cases, when compared to the overall EBV seronegativity of 4.2% of adult solid organ transplant recipients at our institution. EBV seronegativity pre-transplant is a well-known risk factor for EBV-positive PTLD. 71 Although all three of our EBV-SMT cases also had PTLD, in one case early PTLD was an incidental finding on pathology at bowel resection, suggesting that the concurrence of these events may be under-reported in the literature. The frequency of concomitant PTLD in reported post-transplant EBV-SMT cases, particularly in the pediatric setting, suggests a common pathogenesis. We speculate that in that pre-transplant seronegativity and post-transplant primary EBV infection with associated high viral loads may be a unique risk factor for post-transplant EBV-SMT.
A high peak EBV viral load in the setting of primary EBV infection after transplant is known to be common but not specific risk factor for early EBV-positive PTLD. 8, 72, 73 All three of our cases had a diagnosis of PTLD either antecedent or concurrent with their EBV-SMT diagnosis, likely related a primary EBV infection with persistently high peripheral blood EBV viral loads, which were well documented in two of the three cases. Nearly, all reported post-transplant EBV-SMT cases in which data are available had significantly elevated viral loads at diagnosis, though direct comparison of these measurements among centers complicated by the variety of assays used and lack of assay standardization prior to the development of an international standard for EBV DNA measurements. 74 Persistently elevated high EBV viral loads measured in blood occurs commonly in solid organ transplant recipients, particularly those experiencing donor-derived primary EBV infection; these patients are described as having a chronic EBV viral load phenotype. 8 Interestingly, both immunocompetent and transplanted children infected with EBV at a very young age appear to have higher viral loads. 75, 76 This may make young children more vulnerable to concomitant or sequential PTLD and EBV-SMT, as compared to their adult counterparts, which is also suggested by our review of the literature.
Multicenter studies with standardized EBV viral load testing would be required to determine whether specific parameters of EBV viral load kinetics including peak viral load, set-point viral load and "area under the curve" of viral loads in solid organ transplant recipients experiencing primary EBV infection might be predictive of EBV-SMT development and should be considered.
Our post-transplant EBV-SMT cases occurred exclusively in pediatric heart transplant recipients, although comparable number of EBV seronegative pediatric liver allograft recipients of the same age were transplanted at our center during the study period as well as 182 seronegative adult transplant recipients. The fact that posttransplant EBV-SMT did not occur in either of these populations would suggest that risk factors other than EBV seronegativity at diagnosis may also contribute to the increased risk of post-transplant EBV-SMT in pediatric heart transplant patients, such as more aggressive immunosuppression. Another unique aspect of pediatric heart transplantation is the removal of the thymus for surgical The median quantitative viral load in cases where it was reported (n = 13) was 36 000 copies/mL (range 1800-7 × 10 6 copies/mL). Whether measurements were performed in plasma vs whole blood were not specified in these reports. reasons, and thymectomy was performed in all three of our cases.
Thymectomy was found to result in skewed profiles of peripheral T cells and their subpopulations and premature immunosenescence. 
